AAAAAA
Results:
1-22
|
Results: 22
Authors:
Woodruff, NW
Durant, JL
Donhoffner, LL
Penman, BW
Crespi, CL
Citation: Nw. Woodruff et al., Human cell mutagenicity of chlorinated and unchlorinated water and the disinfection byproduct 3-chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX), MUT RES-GTE, 495(1-2), 2001, pp. 157-168
Authors:
Chauret, N
Dobbs, B
Lackman, RL
Bateman, K
Nicoll-Griffith, DA
Stresser, DM
Ackermann, JM
Turner, SD
Miller, VP
Crespi, CL
Citation: N. Chauret et al., The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes, DRUG META D, 29(9), 2001, pp. 1196-1200
Authors:
Abel, S
Beaumont, KC
Crespi, CL
Eve, MD
Fox, L
Hyland, R
Jones, BC
Muirhead, GJ
Smith, DA
Venn, RF
Walker, DK
Citation: S. Abel et al., Potential role for P-glycoprotein in the nonproportional pharmacokinetics of UK-343,664 in man, XENOBIOTICA, 31(8-9), 2001, pp. 665-676
Authors:
Miller, VP
Crespi, CL
Citation: Vp. Miller et Cl. Crespi, High-throughput screening for metabolism-based drug-drug interactions, DRUG PHARM, 114, 2001, pp. 403-414
Authors:
Crespi, CL
Stresser, DM
Citation: Cl. Crespi et Dm. Stresser, Fluorometric screening for metabolism-based drug-drug interactions, J PHARM TOX, 44(1), 2000, pp. 325-331
Authors:
Crespi, CL
Fox, L
Stocker, P
Hu, M
Steimel, DT
Citation: Cl. Crespi et al., Analysis of drug transport and metabolism in cell monolayer systems that have been modified by cytochrome P4503A4 cDNA-expression, EUR J PH SC, 12(1), 2000, pp. 63-68
Authors:
Stresser, DM
Blanchard, AP
Turner, SD
Erve, JCL
Dandeneau, AA
Miller, VP
Crespi, CL
Citation: Dm. Stresser et al., Substrate-dependent modulation of CYP3A4 catalytic activity: Analysis of 27 test compounds with four fluorometric substrates, DRUG META D, 28(12), 2000, pp. 1440-1448
Authors:
Venkatakrishnan, K
Von Moltke, LL
Court, MH
Harmatz, JS
Crespi, CL
Greenblatt, DJ
Citation: K. Venkatakrishnan et al., Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches, DRUG META D, 28(12), 2000, pp. 1493-1504
Authors:
Kawahara, I
Kato, Y
Suzuki, H
Achira, M
Ito, K
Crespi, CL
Sugiyama, Y
Citation: I. Kawahara et al., Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3-B]pyridin-5-yl) methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems, DRUG META D, 28(10), 2000, pp. 1238-1243
Authors:
Grove, AD
Llewellyn, GC
Kessler, FK
White, KL
Crespi, CL
Ritter, JK
Citation: Ad. Grove et al., Differential protection by rat UDP-glucuronosyltransferase 1A7 against benzo[a]pyrene-3,6-quinone- versus benzo[a]pyrene-induced cytotoxic effects inhuman lymphoblastoid cells, TOX APPL PH, 162(1), 2000, pp. 34-43
Authors:
Sata, F
Sapone, A
Elizondo, G
Stocker, P
Miller, VP
Zheng, W
Raunio, H
Crespi, CL
Gonzalez, FJ
Citation: F. Sata et al., CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity, CLIN PHARM, 67(1), 2000, pp. 48-56
Authors:
Stresser, DM
Turner, SD
McNamara, J
Stocker, P
Miller, VP
Crespi, CL
Patten, CJ
Citation: Dm. Stresser et al., A high-throughput screen to identify inhibitors of aromatase (CYP19), ANALYT BIOC, 284(2), 2000, pp. 427-430
Authors:
Crespi, CL
Citation: Cl. Crespi, Assessing the potential for drug-drug interactions in an accelerated throughput mode, PHARM SCI T, 2(3), 1999, pp. 119-120
Authors:
Durant, JL
Lafleur, AL
Busby, WF
Donhoffner, LL
Penman, BW
Crespi, CL
Citation: Jl. Durant et al., Mutagenicity of C(24)H(14)PAH in human cells expressing CYP1A1, MUT RES-GTE, 446(1), 1999, pp. 1-14
Authors:
Hu, M
Li, YQ
Davitt, CM
Huang, SM
Thummel, K
Penman, BW
Crespi, CL
Citation: M. Hu et al., Transport and metabolic characterization of Caco-2 cells expressing CYP3A4and CYP3A4 plus oxidoreductase, PHARM RES, 16(9), 1999, pp. 1352-1359
Authors:
Crespi, CL
Miller, VP
Citation: Cl. Crespi et Vp. Miller, The use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future, PHARM THERA, 84(2), 1999, pp. 121-131
Authors:
Lanza, DL
Code, E
Crespi, CL
Gonzalez, FJ
Yost, GS
Citation: Dl. Lanza et al., Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells, DRUG META D, 27(7), 1999, pp. 798-803
Authors:
Roy, P
Yu, LJ
Crespi, CL
Waxman, DJ
Citation: P. Roy et al., Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles, DRUG META D, 27(6), 1999, pp. 655-666
Authors:
Busby, WF
Ackermann, JM
Crespi, CL
Citation: Wf. Busby et al., Effect of methanol, ethanol, dimethyl sulfoxide, and acetonitrile on in vitro activities of cDNA-expressed human cytochromes P-450, DRUG META D, 27(2), 1999, pp. 246-249
Authors:
Pedersen, DU
Durant, JL
Penman, BW
Crespi, CL
Hemond, HF
Lafleur, AL
Cass, GR
Citation: Du. Pedersen et al., Seasonal and spatial variations in human cell mutagenicity of respirable airborne particles in the northeastern United States, ENV SCI TEC, 33(24), 1999, pp. 4407-4415
Authors:
Crespi, CL
Miller, VP
Penman, BW
Citation: Cl. Crespi et al., High throughput screening for inhibition of cytochrome p450 metabolism, MED CHEM RE, 8(7-8), 1998, pp. 457-471
Authors:
Fairbrother, KS
Grove, J
de Waziers, I
Steimel, DT
Day, CP
Crespi, CL
Daly, AK
Citation: Ks. Fairbrother et al., Detection and characterization of novel polymorphisms in the CYP2E1 gene, PHARMACOGEN, 8(6), 1998, pp. 543-552
Risultati:
1-22
|